These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6339270)

  • 1. Successful treatment of autoimmune manifestations in MRL/l and MRL/n mice using total lymphoid irradiation (TLI).
    Moscovitch M; Rosenmann E; Neeman Z; Slavin S
    Exp Mol Pathol; 1983 Feb; 38(1):33-47. PubMed ID: 6339270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT).
    Karussis DM; Vourka-Karussis U; Lehmann D; Abramsky O; Ben-Nun A; Slavin S
    Clin Exp Immunol; 1995 Apr; 100(1):111-7. PubMed ID: 7697909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of nzb/nzw disease with total lymphoid irradiation.
    Kotzin BL; Strober S
    J Exp Med; 1979 Aug; 150(2):371-8. PubMed ID: 313431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of autoimmune disease in (NZB/NZW)F1 female mice by using fractionated total lymphoid irradiation.
    Slavin S
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5274-6. PubMed ID: 291944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment of autoimmune MRL/Mp-lpr/lpr mice with cholera toxin plus irradiation. Combined treatment of autoimmune MRL/l mice.
    Fan JL; Himeno K; Hussain A; Nomoto K
    Biotherapy; 1989; 1(2):97-102. PubMed ID: 2641464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
    J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of lupus dermatoses in autoimmune mice. XIX. Attempts to induce subepidermal immunoglobulin deposition in MRL/Mp- +/+ mice.
    Furukawa F; Ohshio G; Imamura S
    Arch Dermatol Res; 1993; 285(1-2):20-6. PubMed ID: 8470930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lupus erythematosus cell formation by a monoclonal antibody derived from an autoimmune MRL/Mp-lpr/lpr mouse.
    Kanai Y; Yamauchi S; Hashiba-Kanai Y
    Immunol Lett; 1989 Jan; 20(1):9-13. PubMed ID: 2469647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of autoimmune MRL/Mp-lpr/lpr mice with cholera toxin.
    Fan JL; Himeno K; Tsuru S; Nomoto K
    Clin Exp Immunol; 1987 Oct; 70(1):94-101. PubMed ID: 3500817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation therapy of spontaneous autoimmunity: a review of mouse models.
    Loor F; Jachez B; Montecino-Rodriguez E; Klein AS; Kuntz L; Pflumio F; Fonteneau P; Illinger D
    Int J Radiat Biol Relat Stud Phys Chem Med; 1988 Jan; 53(1):119-36. PubMed ID: 2892809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).
    Katzav A; Kloog Y; Korczyn AD; Niv H; Karussis DM; Wang N; Rabinowitz R; Blank M; Shoenfeld Y; Chapman J
    Clin Exp Immunol; 2001 Dec; 126(3):570-7. PubMed ID: 11737078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte migration patterns in autoimmune MRL-lpr/lpr mice: relationship to age, disease manifestations and lymphocyte homing receptor expression.
    Schrieber L; Manolios N; Cohen MG; Paull SA; Guiffre AK; Hopper KE
    Autoimmunity; 1989; 3(1):5-15. PubMed ID: 2491620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation.
    Ikehara S; Yasumizu R; Inaba M; Izui S; Hayakawa K; Sekita K; Toki J; Sugiura K; Iwai H; Nakamura T
    Proc Natl Acad Sci U S A; 1989 May; 86(9):3306-10. PubMed ID: 2654943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fate of immune complexes, glomerulonephritis, and cell-mediated vasculitis in lupus-prone MRL/Mp lpr/lpr mice.
    Cruse JM; Lewis RE; Dilioglou S
    Exp Mol Pathol; 2000 Dec; 69(3):211-22. PubMed ID: 11115362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total lymphoid irradiation as an immunosuppressive agent for transplantation and the treatment of 'autoimmune' disease: a review.
    Halperin EC
    Clin Radiol; 1985 Mar; 36(2):125-30. PubMed ID: 3933886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice.
    Takahashi S; Fossati L; Iwamoto M; Merino R; Motta R; Kobayakawa T; Izui S
    J Clin Invest; 1996 Apr; 97(7):1597-604. PubMed ID: 8601623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. beta2-microglobulin dependence of the lupus-like autoimmune syndrome of MRL-lpr mice.
    Christianson GJ; Blankenburg RL; Duffy TM; Panka D; Roths JB; Marshak-Rothstein A; Roopenian DC
    J Immunol; 1996 Jun; 156(12):4932-9. PubMed ID: 8648144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Fas lpr mice.
    Iwata Y; Wada T; Furuichi K; Sakai N; Matsushima K; Yokoyama H; Kobayashi K
    J Am Soc Nephrol; 2003 Jan; 14(1):57-67. PubMed ID: 12506138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptible cytotoxicity to ultraviolet B light in fibroblasts and keratinocytes cultured from autoimmune-prone MRL/Mp-lpr/lpr mice.
    Furukawa F; Lyon MB; Norris DA
    Clin Immunol Immunopathol; 1989 Sep; 52(3):460-72. PubMed ID: 2474396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine therapy suppresses ocular and lacrimal gland disease in MRL/Mp-lpr/lpr mice.
    Jabs DA; Lee B; Burek CL; Saboori AM; Prendergast RA
    Invest Ophthalmol Vis Sci; 1996 Feb; 37(2):377-83. PubMed ID: 8603842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.